99 completed, 27 terminated, 22 unknown, 13 recruiting. 178 Phase 2, 21 Phase 1, 1 Phase 3.
Follow Panitumumab: new trials by email Literature Review of Panitumumab trials Research Report on Panitumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer VS-7375, cetuximab, panitumumab - Colorectal Cancer | Phase 2 | Recruiting | Verastem, Inc. | 150 | 2026-07-28 | 2026-11-19 |
| 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC 89Zr-panitumumab IV, Panitumumab - Head-and-neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Andrei Iagaru | 2026-06-01 | 2026-08-17 | |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation Sotorasib, Panitumumab - Advanced Solid Tumors | Phase 2 | Recruiting | Amgen | 14 | 2026-01-02 | 2026-11-20 |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin - Metastatic Colorectal Cancer | Phase 2 | Recruiting | AbbVie | 390 | 2025-04-24 | 2026-10-27 |
| Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 73 | 2025-03-21 | 2025-12-10 |
| ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer irinotecan, panitumumab, Valproic Acid (VPA) - Colorectal Cancer Metastatic | Phase 2 | Recruiting | National Cancer Institute, Naples | 130 | 2025-03-12 | 2025-12-17 |
| A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms | Phase 2 | Recruiting | Blokhin's Russian Cancer Research Center | 64 | 2025-03-01 | 2025-05-18 |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer Botensilimab, Balstilimab, Oxaliplatin - Colorectal Cancer | Phase 2 | Active not recruiting | Nicholas DeVito, MD | 16 | 2024-11-18 | 2026-02-05 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients 166Holmium TARE, Cetuximab, Panitumumab - Colorectal Cancer Metastatic | Phase 2 | Terminated | Gruppo Oncologico del Nord-Ovest | 4 | 2024-03-13 | 2026-01-05 |
| A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab Oral sotorasib + IV Panitumumab - Efficacy | Phase 2 | Unknown | Korea University Anam Hospital | 24 | 2023-07-03 | 2023-08-15 |
| Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Trastuzumab deruxtecan, Durvalumab, Panitumumab - Colorectal Cancer, Resectable Colorectal Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 197 | 2023-05-11 | 2026-09-11 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 623 | 2023-04-18 | 2026-11-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-18 |
| Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer Sodium Valproate, Panitumumab, Cetuximab - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | Australasian Gastro-Intestinal Trials Group | 38 | 2023-01-23 | 2026-05-08 |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab - Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer | Phase 2 | Terminated | Northwestern University | 7 | 2022-10-10 | 2026-06-12 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab CEND-1, Panitumumab, Folfirinox - Colon Cancer, Pancreas Cancer | Phase 1 / Phase 2 | Unknown | Anup Kasi | 50 | 2021-10-20 | 2024-12-17 |
| PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence Regorafenib, Panitumumab - Colorectal Cancer | Phase 2 | Completed | Gruppo Oncologico del Nord-Ovest | 213 | 2020-12-15 | 2026-08-28 |
Showing 20 of 178. Sign in to see all of them.
Colorectal Neoplasms (84) · Colonic Neoplasms (22) · Rectal Neoplasms (21) · Neoplasm Metastasis (20) · Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (9) · Esophageal Neoplasms (8) · Cholangiocarcinoma (7) · Breast Neoplasms (6) · Carcinoma, Squamous Cell (6) · Head and Neck Neoplasms (6) · Lung Neoplasms (6) · Pancreatic Neoplasms (6) · Adenocarcinoma Of Esophagus (4) · Carcinoma (4)
Amgen (24) · M.D. Anderson Cancer Center (6) · Vejle Hospital (6) · Grupo Espanol Multidisciplinario del Cancer Digestivo (5) · Gruppo Oncologico del Nord-Ovest (5) · AIO-Studien-gGmbH (4) · Memorial Sloan Kettering Cancer Center (4) · UNICANCER (4) · WiSP Wissenschaftlicher Service Pharma GmbH (4) · Alliance for Clinical Trials in Oncology (3) · Federation Francophone de Cancerologie Digestive (3) · National Cancer Institute (NCI) (3) · National Cancer Institute, Naples (3) · SCRI Development Innovations, LLC (3) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (3)
United States (73) · Italy (19) · Spain (19) · France (18) · Germany (15) · Belgium (9) · Netherlands (8) · Denmark (7) · Australia (6) · Austria (6) · Canada (6) · Japan (6) · United Kingdom (5) · Greece (4) · Switzerland (4)
Anders Jakobsen, DMSc (2) · Anders Jakobsen, MD, DMSc (2) · Antonio Arrivi, MD (2) · Aram Hezel, MD (2) · Jaime Feliu, MD (2) · Joan Maurel, MD (2) · Jorge Aparicio, MD (2) · Nancy Kemeny, MD (2) · Ruth Vera, MD (2) · Vicente Alonso, MD (2)
PMID 18316791, PMID 22070868, PMID 26049686, PMID 34213592, PMID 38592721, PMID 10744089, PMID 10918161, PMID 11247898, PMID 15175435, PMID 15210739, PMID 15870084, PMID 16943526, PMID 17470860, PMID 17671985, PMID 17785764, PMID 18407737, PMID 18506163, PMID 19097774, PMID 19287023, PMID 19339720, PMID 19755046, PMID 21090969, PMID 22000810, PMID 22210091, PMID 22367707, PMID 23041588, PMID 23139259, PMID 23359181, PMID 24138831, PMID 24146220, PMID 24562448, PMID 24827135, PMID 25596660, PMID 25963019, PMID 26094080, PMID 26183044, PMID 26540314, PMID 26818619, PMID 26911408, PMID 27733374, PMID 27865372, PMID 28284575, PMID 28592616, PMID 28945848, PMID 29259073, PMID 29370781, PMID 29413685, PMID 29501977, PMID 29769385, PMID 29855806
2009 (12), 2016 (5), 2008 (3), 2017 (3), 2015 (2), P30CA015083 (2), R01CA190306 (2), U10CA180820 (2), P30CA036727 (1), P30CA060553 (1), P30CA138292 (1), U10CA076001 (1)